Mirati Therapeutics Stock Forecast, Price & News

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Mirati Therapeutics stock.
View analyst ratings for Mirati Therapeutics or view top-rated stocks.

Wall Street analysts have given Mirati Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mirati Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Mirati Therapeutics.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) posted its quarterly earnings results on Thursday, February, 25th. The biotechnology company reported ($2.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($2.23) by $0.15. The biotechnology company had revenue of $1.71 million for the quarter, compared to analysts' expectations of $1 million.
View Mirati Therapeutics' earnings history.

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRTX stock has increased by 112.0% and is now trading at $164.05.
View which stocks have been most impacted by COVID-19.

16 analysts have issued 12 month price targets for Mirati Therapeutics' shares. Their forecasts range from $116.00 to $285.00. On average, they expect Mirati Therapeutics' stock price to reach $218.57 in the next year. This suggests a possible upside of 33.2% from the stock's current price.
View analysts' price targets for Mirati Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Mirati Therapeutics include Shiseido (SSDOY), Astellas Pharma (ALPMY), BeiGene (BGNE), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), Genmab A/S (GMAB), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Genmab A/S (GNMSF), Horizon Therapeutics Public (HZNP), CureVac (CVAC), UCB (UCBJF), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Zai Lab (ZLAB) and BioMarin Pharmaceutical (BMRN).
View all of MRTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Square (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Mirati Therapeutics stock include Avoro Capital Advisors Llc, Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Isan Chen, Jamie A Donadio, Ltd Braslyn, Maria E Martinez, Michael G Grey and Vickie S Reed.
View institutional ownership trends for Mirati Therapeutics.

MRTX stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Mirati Therapeutics company stock in the last year include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Isan Chen, Ltd Braslyn, Maria E Martinez, and Vickie S Reed.
View insider buying and selling activity for Mirati Therapeutics or view top insider-selling stocks.

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRTX stock can currently be purchased for approximately $164.05.

Mirati Therapeutics has a market capitalization of $8.31 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis.

Mirati Therapeutics employs 199 workers across the globe.

The official website for Mirati Therapeutics is www.mirati.com.

Mirati Therapeutics is headquartered at 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]